Research at Oslo University Hospital


Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.


Latest news

Lars Tjelta Westlye appointed "Scientist of the Month" by "Helse Sør-Øst" for the May 2017

Lars T. Westlye
Lars T. Westlye

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".

For the month of May 2017, this honour went to Lars Tjelta Westlye, senior scientist at the The Norwegian Centre for Mental Disorders Research (NORMENT). The centre is based on a collaboration between the University of Oslo (host institution), the University of Bergen and Oslo University Hospital, where Westlye has a position at the psychosis research section at the Division of Mental Health and Addiction.


Call for applications 2018

Annuncement of research funding from South-East Norway regional health authority for 2018


The South-Eastern Norway Regional Health Authority hereby announces a call for applications for research projects and research activities starting in 2018.

The total funding available for this call is approximately 100 million Norwegian kroner.

Application deadline is Tuesday, September 5th 2017 kl. 16:00.


Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2016

Award winners during the ceremony (photo Marethe Falch)
Award winners during the ceremony (photo Marethe Falch)

Six research groups were awarded for their excellent papers published during the second half-year of 2016 during a ceremony June 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.


Innovation project from the Lind group featured by GenomeWeb


The New York based news organization GenomeWeb recently presented an in-depth article about the Oslo University Hospital-efforts of developing a urine-based test for monitoring of bladder cancer patients. Professor Guro Lind presented the project at the Oslo Life Science Conference 2017 previously this year (watch presentation, 58 minutes into the recording. The project drew the attention of Bjarne Røsjø in Titan and was later picked up by GenomeWeb.


Clinically important genetic heterogeneity in colorectal cancers with microsatellite instability

First authors Anita Sveen, Torstein Tengs and Bjarne Johannessen (contributed equally)
First authors Anita Sveen, Torstein Tengs and Bjarne Johannessen (contributed equally)

Microsatellite instability (MSI) defines a small subgroup of approximately 15% of colorectal cancers (CRC) which currently receives much attention due to its overall good response to immune-checkpoint inhibition. In the latest issue of Genome Medicine, scientist Anita Sveen and colleagues publish the largest multilevel genetic analysis of this tumor type reported to date, describing substantial inter- and intra-tumor heterogeneity. The clinical importance of these results, in particular with respect to the optimized use of immunotherapeutics for treatment of human cancers, was emphasized in a Research Highlight in the same issue of the journal.


Per O. Seglen awarded King Olav V's cancer research prize for 2017

Per Ottar Seglen received the award from H.M. King Harald V and was congratulated by Anne Lise Ryel and Gunn-Elin Aa. Bjørneboe
Per Ottar Seglen received the award from H.M. King Harald V and was congratulated by Anne Lise Ryel and Gunn-Elin Aa. Bjørneboe

King Olav V's cancer research prize for 2017 was on June 6th given to professor Per O. Seglen, formerly head of the Proteomics & Mammalian Cell Biology Section at the Institute for Cancer Research, OUH, currently a guest researcher at NCMM.

The prestigious prize is distributed annually by the Norwegian Cancer Society, and the winner receives NOK 1.000.000.


New mechanism for rare skin disorder discovered

Jan C. Sitek
Jan C. Sitek

Norwegian scientists have found the genetic cause of the skin disease KWE (keratolytic winter erythema) - a rare autosomal-dominant skin disorder characterized by recurrent episodes of palmoplantar erythema and epidermal peeling, usually triggered by cold weather, moisture, or stress.
In an article recently published in the American Journal of Human Genetics (journal impact factor 10.8) it is concluded that KWE is caused by tandem duplications in a non-coding genomic region containing an active enhancer element for CTSB, a gene encoding cathepsin B, resulting in upregulation of the protein in affected individuals.
The article was selected as "Editors choice" in AJHG for the month of May.
Head physician  and 2nd author of the paper Jan Cezary Sitek (photo) from the Dermatology Research Group at Oslo University Hospital initiated the research project six years ago, and treats several patients with KWE.


Less expensive medicine results in treatment for more patients

Norwegian research with international impact

Lancet article Norwegian co-authors
Lancet article Norwegian co-authors

A Norwegian randomized clinical trial shows that it is safe to change from expensive originator medicine to a less expensive biosimilar product. The effect is the same but the costs are reduced more than 50% in Norway. This means that more patients can receive this important treatment. The results of the study are now published in one of the world’s most recognised medical journals, The Lancet (journal impact factor 44.0). The findings have been covered by the Norwegian Broadcasting Corporation (NRK).
Scientists participating in the study affiliated to Oslo University Hospital were Merete Lorentzen (shared first authorship), Knut Lundin and Nils Bolstad.


The 2017 Excellent Research Awards to Kirsten Sandvig, Johannes Espolin Roksund Hov and Tor Paaske Utheim

From left: Johannes Espolin Roksund Hov, Kirsten Sandvig and Tor Paaske Utheim.
From left: Johannes Espolin Roksund Hov, Kirsten Sandvig and Tor Paaske Utheim.

Three scientists received awards for their outstanding research at a ceremony taking place at Oslo University Hospital May 5th.

The major prize - the "Excellent Researcher Award" - went to professor Kirsten Sandvig.
Johannes Espolin Roksund Hov and Tor Paaske Utheim both received the "Early Career Award".

The prize money - 300.000 and 150.000 NOK respectively - is earmarked for research activities. This prize is distributed anually in order to honour excellent scientific work.


New insight into late effects after cancer treatment presented by the Norwegian Cancer Society

Cecilie Kiserud
Cecilie Kiserud

The Norwegian Cancer Society present research they support regularly, in a popular science form, and they have recently published a feature article on late effects after cancer treatment.
Cecilie Kiserud, head of the National Advisory Unit on Late Effects after Cancer Treatment at the Department of Oncology, has been interviewed about their research activites and new insight into life after cancer, a field that has gained more attention the recent years.